Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints
Oh W. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urologic Oncology Seminars And Original Investigations 2003, 21: 229-234. PMID: 12810211, DOI: 10.1016/s1078-1439(03)00019-x.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAndrogen AntagonistsAndrogensAntineoplastic AgentsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBiomarkersChemotherapy, AdjuvantEstramustineFlutamideHumansLeuprolideMaleNeoadjuvant TherapyNeoplasms, Hormone-DependentPalliative CareProstatectomyProstatic NeoplasmsRandomized Controlled Trials as TopicRiskConceptsHigh-risk localized prostate cancerLocalized prostate cancerProstate cancerClinical parameters of efficacyNeoadjuvant androgen deprivation therapyManagement of localized diseaseDefinitive local therapyDefinitive local treatmentHormone-refractory settingAndrogen deprivation therapyRisk of recurrenceMolecular targeted therapyParameters of efficacyAndrogen-dependent diseasesDeprivation therapyNeoadjuvant therapyRadical prostatectomyLocal therapySystemic therapyLocalized diseaseClinical parametersRandomized studyLocal treatmentEarly diseaseTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply